Galmed Pharmaceuticals is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases.

Its lead compound, Aramchol, a backbone drug candidate for the treatment of NASH and fibrosis is currently in a Phase 3 registrational study.

The company is also collaborating with the Hebrew University in the development of Amilo-5MER, a 5 amino acid synthetic peptide and recently initiated a first in human study.